Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Some Muss and Fuss over at Sequenom
By:
TraderMark
Wednesday, January 14, 2009 7:42 AM
Symbols:
SQNM
Email Article
Bookmark:
Font Size
Print Article
Earlier in the day, however, analysts appeared to doubt that idea.
Oppenheimer analyst Kevin DeGeeter said the company is reporting minimal sales -- it reported negative $700,000 in revenue during the third quarter -- and
has less than six months of cash left.
That made other offers unlikely in his view.
DeGeeter said Sequenom's offer presented a "great deal" for Exact Sciences, but he said Sequenom does not need to complete the deal and will probably not chase Exact Sciences.
In announcing its offer Friday afternoon, Sequenom said cancer screening is an important field for the company. It
believes Exact Sciences' cancer tests fit well with Sequenom's own MassArray genetic research systems and other DNA tests
.
In a client note, Lazard Capital Markets analyst Sean Lavin said the deal would help Sequenom fulfill its goal of developing noninvasive cancer diagnostic tests. He wrote that
Exact Sciences is one of the leading colon cancer diagnostic companies, and holds valuable patents. It also has relationships with key doctors, which could help sell its products
, he said.
Lavin, who rates Sequenom at "Buy," b
elieves that Sequenom would gain additional patent protection on its own products if it buys Exact Sciences' intellectual property. But he said the patents on SEQureDx should hold up even if no deal is made
. "Contrary to some market chatter, Exact Sciences does not seem to have any IP that would prevent Sequenom from launching its Down test even if this acquisition does not go through," he wrote.
Long Sequenom in fund and personal account
Next Page >>
<< Previous Page
1
2
Bookmark:
Email Article
Print Article
Related Stories
Research Related Stocks:
SQNM
,
More Articles on:
Medical
Skymark Research Initiates Independent Research Coverage on Sequenom, Inc.
US Stock Futures Point To Higher Open, Tiffany (NYSE: TIF) Eyed
As Bank Failures Grow, FDIC Options Narrow
Can U.S. Bank Stocks Double Again In 2010?
Credit Market Overview: Nov 24, 2009
Rate this Commentary
Comments
(0)
No Comments
Post Comment
Name:
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
Advertisement
Related Press Releases
Analyst Choice Initiates Market Analysis on Healthcare, Technology and Consumer Goods Sectors
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
SEQUENOM Announces August 6 Webcast of Financial and Other Business Results
SEQUENOM Announces Launch of MassARRAY Compact 96 System
University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
Popular Articles
Can U.S. Bank Stocks Double Again In 2010?
By:
Money Morning
Warning: You May Not Be Making As Much On Gold As You Think
By:
Money Morning
Ten Reasons For Buying Activision Blizzard (ATVI)
By:
Asif Suria
Bears In Trouble? Super Dividends
By:
Marc Courtenay
A Winning Investment Strategy
By:
Dividends4Life
Advertisement
Recent Articles by TraderMark
India Potentially Considering Buying The Other Half of the IMF's 400 Tons Of Gold (GLD) For Sale
Bloomberg: Investors Rushing To Alternative Mutual Funds From JPMorgan (JPM) To Pimco
LDK Solar (LDK) Kicks Off Speculation Week With A Roar
Natural Gas Down 12% On The Month; True Indicator Of State Of Economy
'Houston, We Have A (Russell 2000) Problem'
More Homes In The US In Delinquency Or Foreclosure, Than For Sale
Advertisement
More Articles by:
TraderMark
More Articles on:
Medical
Research Related Stocks:
SQNM
,
Subscribe to
Email Alerts
or
RSS feeds
for articles from more than 300 contributors and press releases, SEC filings and full text news from thousands of sources.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia